Palo Alto Investors’s Aclaris Therapeutics ACRS Stock Holding History

Palo Alto Investors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.54M	Hold	1,613,430	–	–	1.18%	25
2026 Q1	$6.05M	Buy	1,613,430 +46,590	+3%	+$157K	0.93%	28
2025 Q4	$4.72M	Hold	1,566,840	–	–	0.66%	30
2025 Q3	$2.98M	Buy	1,566,840 +176,812	+13%	+$308K	0.55%	28
2025 Q2	$1.97M	Buy	1,390,028 +614,000	+79%	+$831K	0.42%	29
2025 Q1	$1.19M	Buy	776,028 +206,196	+36%	+$440K	0.23%	34
2024 Q4	$1.41M	Hold	569,832	–	–	0.22%	32
2024 Q3	$655K	Hold	569,832	–	–	0.09%	40
2024 Q2	$627K	Hold	569,832	–	–	0.07%	37
2024 Q1	$707K	Buy	+569,832	New	+$680K	0.08%	37

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Palo Alto Investors's ACRS Position: Q2 2026 in Review

Palo Alto Investors held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 1,613,430 shares worth $8.54M. The position accounts for 1.18% of the portfolio, ranked #25.

Palo Alto Investors first reported a position in ACRS in Q1 2024 and has held it in 10 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Palo Alto Investors held 1,613,430 shares of Aclaris Therapeutics worth $8.54M as of Q2 2026.
Palo Alto Investors left its Aclaris Therapeutics share count unchanged in Q2 2026.
Aclaris Therapeutics made up 1.18% of Palo Alto Investors's portfolio in Q2 2026, its #25 holding.
Palo Alto Investors first reported a position in Aclaris Therapeutics in Q1 2024 and has held it in 10 quarters since.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.